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SUMMARY  
 
 
Background 
 
Osteoporosis is a common clinical problem, and has been increasingly recognised to 
occur in patients with inflammatory bowel disease (IBD) in whom a reduction in bone 
mineral density (BMD) has been widely reported. A number of studies have emerged in 
recent years indicating that tumour necrosis factor (TNF) blockade appears to have a 
beneficial effect on BMD in IBD patients.  
 
Aims 
To provide a review of the available data regarding the effect of the currently licensed 
anti-TNF-α therapies on bone metabolism and BMD in IBD patients.  
 
Methods 
A Medline search was performed using the search terms ‘infliximab’, ‘bone metabolism’, 
‘IBD’, ‘BMD’, ‘bone markers’, ‘adalimumab’, ‘bone disease’, ‘Crohn’s disease’, and 
‘ulcerative colitis’.  
 
Results 
Infliximab has a beneficial effect on bone turnover markers in Crohn’s disease patient in 
short term. There is little data looking at the effect of anti-TNF-α therapy on bone 
metabolism in ulcerative colitis patients. Moreover, the long term effects of anti-TNF-α 
therapy on bone structure and fracture risk in IBD patients are currently not known. The 
effect of cessation of anti-TNF-α therapy on bone metabolism is also unknown.  
 
Conclusions 
Properly controlled long term trials are needed to fully evaluate the effect of TNF 
blockade in this regard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
MAIN TEXT 
 
INTRODUCTION 
     IBD comprises a group of disorders of the gastrointestinal tract characterized by 
chronic intestinal inflammation and a chronic relapsing course. IBD has traditionally 
been categorized as either ulcerative colitis (UC) or Crohn’s disease (CD) on the basis of 
clinical, radiological, endoscopic and histological criteria. Both UC and CD are 
commonly characterized by a series of clinical exacerbations and remissions requiring 
long term use of medications, and not frequently, surgical interventions. CD may involve 
the entire gastrointestinal tract from mouth to perianal area, whereas in UC the 
inflammation is confined to the large bowel. Multiple other organ systems can be affected 
in IBD, including the bones and joints, skin, eyes, hepatobiliary system, lungs and 
kidneys. Collectively, these are called extra-intestinal manifestations of IBD, and they 
can occur prior to, in conjunction with, or subsequent to active bowel disease. The overall 
prevalence of any extra-intestinal manifestations in IBD patients ranges from 21%-40%.
1-
3
 In most large studies of IBD, the prevalence of extra-intestinal manifestations is higher 
in CD compared to UC.
2-4
  
     Bone demineralization and osteoporosis in patients with IBD was first reported about 
30 years ago.
5
  The largest risk was observed at the spine, particularly in women, with a 
6.5 fold increase in fracture risk.
6
  In a recent population based cohort study, the relative 
risk of hip fracture was 1.41 (0.94-2.11) for UC and 1.68 (1.01-2.78) for CD patients.
7
 
This study also concluded that the risk of hip fracture is increased approximately 60% in 
IBD patients and the majority of hip fracture risk in IBD patients cannot be attributed to 
steroid use.
7
  
    The pathogenesis of reduced bone mineral density (BMD) in IBD is multi-factorial. As 
seen in the general population, factors such as age, gender, estrogen deficiency, 
alterations in calcium homeostasis, nutritional and dietary factors, smoking, alcohol and 
immobility may play a role. Vitamin D deficiency,
8,9
 glucocorticoid treatment,
10-13
 
hypogonadism,
14
 and Vitamin K deficiency
15,16
 also have been shown to cause bone loss 
in some IBD patients. However, emerging evidence suggests that these factors play a 
relatively weak role in the pathogenesis of BMD loss in IBD and are overshadowed by 
the effect of the IBD itself.
10,17-19
 Newly diagnosed untreated IBD patients been reported 
to have reduced BMD.
20
 Recently, active inflammation and elevated pro-inflammatory 
cytokines have been implicated in the pathogenesis of bone resorption in a variety of 
models.
21-26 
Circulating pro-inflammatory cytokine levels are elevated in IBD patients 
with active inflammation
27-29 
suggesting that disease activity and high cytokine levels 
could also play a role in IBD related bone disease. A rat model of colitis was associated 
with a dramatic 33% loss in trabecular bone and an even greater suppression in bone 
formation rate.
30
 Healing of colitis was associated with an increased bone formation rate 
and a return of bone measurements to normal levels. Serum from children with CD 
affects bone mineralization in an organ culture model without altering bone resorption.
16
  
These observations suggest that mediators produced during intestinal inflammation may 
alter osteoblast function and bone formation, and they are consistent with the observation 
that osteoporotic patients with IBD have higher serum interleukin (IL)-6 levels than non 
osteoporotic patients. There is a strong case for suggesting that demineralization in 
patients with IBD occurs primarily as a consequence of the intestinal inflammation.  
    TNF-α, IL -1β and IL-6, amongst others, are potent activators of bone resorption at low 
concentrations in vitro.
24,31,32
  The mechanisms of actions are multiple, including 
stimulation of osteoclast differentiation
33-35
 and activation
36
 with concomitant inhibition 
of osteoclast apoptosis
.37
 TNF-α also inhibits osteoblast differentiation38 and TNF-α, IL-
1β and IL-6 reduce bone formation in cultured osteoblasts.32,39 Like, IL-1, TNF-
stimulated induction of osteoclast like cells formation in bone marrow culture
40
 is 
mediated by increases in receptor activator of NF kappa ligand (RANKL) expression.
41
 
However, in addition to increasing RANKL expression TNF also stimulates 
osteoprotegerin (OPG) in osteoblastic model.
42
 Thus, pro-inflammatory cytokines 
potentially cause bone loss by both increasing bone resorption and inhibiting bone 
formation. In IBD patients, elevated TNF-α are noted not only in patients with active 
disease but even in patients with inactive disease who have morphologically normal 
intestinal biopsies
43
 and recently is suspected of being an important mediator of bone loss 
in this group of patients.
44,45
  
    The signaling system that normally maintains coupled bone remodeling has not been 
well defined, although it is clear that excessive osteoclastic bone resorption or defective 
osteoblast synthesis creates a dysequilibrium, with a net loss in bone mass. The initial 
step in the remodeling process involves osteoclastogenesis through a process of 
sequential proliferation, differentiation, and activation of mononuclear precursors. The 
recent discovery of an elegant receptor-based interaction between osteoblast and 
osteoclast precursors appears to provide this "missing link" and simultaneously integrates 
this system with the immune response. Osteoblasts express a surface ligand RANKL that 
can bind to osteoclast precursors (the RANK) or an osteoblast-derived soluble decoy 
receptor known as OPG.
46
 The binding of RANK to RANKL induces a signaling and 
gene expression cascade that results in differentiation and maturation of osteoclasts. OPG 
blocks this interaction, thereby inhibiting osteoclast formation. RANKL is also a 
regulator of T cell–dendritic cell interaction in the immune system and is a crucial factor 
in early lymphocyte development and lymph node organogenesis.
47
 The central 
importance of this system is seen in RANKL gene–deficient mice that are unable to 
support osteoclast differentiation, display severe osteopetrosis (even in the presence of 
bone-resorbing factors, such as vitamin D3, dexamethasone, and PGE2), show no 
evidence of bone remodeling, and simultaneously lack all lymph nodes.
48
 There is 
emerging evidence that the RANKL–OPG system may be the final common pathway for 
many of the classical bone-active agents.  The discovery of the RANK ligand pathway 
and its inhibition by OPG has had important implications for bone physiology as well as 
inflammation research. These interactions suggest that TNF-α blockade may have 
beneficial effect on bone generally. Unfortunately, data regarding the effect of TNF-α 
blockade on BMD and bone metabolism in IBD patients in clinical setting are limited. In 
this review article, we aim to review the available data regarding the effect of anti-TNF-α 
therapy on bone metabolism and BMD in IBD patients.  
 INFLIXIMAB  
         Infliximab is a chimeric IgG1 monoclonal antibody comprised of 75% human and 
25% murine sequences, which has a high specificity for and affinity to TNF-α. Infliximab 
neutralizes the biologic activity of TNF-α by inhibiting binding to its receptors. However, 
infliximab's mechanism of action most likely involves the destruction of activated 
effector cells bearing receptor bound TNF-α through apoptosis and/or other 
mechanisms.
49-53
 Infliximab has a half life of approximately 10 days. Infliximab is the 
first biologic agent to be licensed for use in IBD patients. Besides its use in IBD, 
infliximab is also licensed for use in rheumatoid arthritis (RA), plaque psoriasis, psoriatic 
arthritis and ankylosing spondylitis.  
    Infliximab is approved for the treatment of moderate to severe CD patients who have 
not responded well to other conventional therapies.
54,55
 In clinical studies, infliximab has 
been shown to decrease histologic and endoscopic disease activity and to induce and 
maintain remission in patients with active CD. Infliximab is also approved for use in 
fistulizing CD patients based upon the results of two randomized controlled trials.
56,57
 
Accumulating evidence has suggested that scheduled, maintenance therapy with 
infliximab has substantial clinical benefits compared with episodic treatment in CD 
patients who achieved remission with initial infliximab induction therapy.
58
 For this 
reason most centers have now moved to scheduled as opposed to episodic maintenance 
therapy.  
     Infliximab is the first and only biologic currently approved for the treatment of 
moderate to severe UC failing to respond to conventional therapies.
59
 In clinical studies, 
infliximab treatment was associated with achievement of clinical response and clinical 
remission, mucosal healing and elimination of corticosteroid use. Despite its now 
widespread use in inflammatory disorders, only limited data exist on the role of 
infliximab on the bone metabolism in IBD patients. Furthermore most of the published 
data pertain to small cohorts of patients.  
 
INFLIXIMAB AND BONE MARKERS  
     The first studies to suggest that a beneficial effect was seen with TNF blockade on 
bone metabolism in IBD patients were published in 2004. Franchimont et al.
60
 studied 71 
CD patients treated for the first time with infliximab (5mg/kg) for refractory CD and 
compared their results to 68 healthy control population matched for age and gender with 
this CD patients. The study included 21 fistulizing refractory CD patients and 50 luminal 
refractory CD patients. Patients were treated with a single infusion of 5mg/kg infliximab 
at baseline for refractory disease and with three infusions of 5mg/kg infliximab at 
baseline, week 2 and week 6 for fistulizing refractory disease. Serum samples for bone 
for bone formation markers; bone alkaline phosphatase (b-ALP),  osteocalcin (OC) and 
pro-collagen type 1 N propeptide (P1NP) and serum samples for bone resorption markers 
carboxyterminal telopeptide (sCTx) were measured at baseline and 8 weeks after 
completion of infliximab treatment (week 8 for refractory luminal CD and week 14 for 
refractory fistulizing CD). Clinical activity of the disease based of Crohn’s Disease 
Activity Index (CDAI) score and C-reactive protein (CRP) levels were also measured in 
this study at baseline and 4 weeks after completion of therapy as a marker of biological 
response. In this study, the authors observed serum concentration of the bone formation 
markers; b-ALP, OC and P1NP were lower in CD before infliximab treatment than in 
healthy controls while they return to normal levels after infliximab treatment at eight 
weeks. The authors reported that a relevant improvement in bone formation (defined as 
an increase of at least 30% in the bone formation marker) was found after infliximab 
treatment in 29.7%, 60.8% and 46.5% of the patients when considering b-ALP, OC or 
P1NP as marker, respectively. Serum concentration of sCTx was significantly increased 
in CD at baseline but no longer different from controls after infliximab treatment at eight 
weeks. Relevant improvement in bone resorption (decrease of at least 30% in sCTx 
serum levels) was found after infliximab treatment in 38.2% of patients. The authors 
concluded that in their study infliximab showed a significant and rapid normalization in 
the biochemical markers of bone turnover in CD treated patients and that this could 
probably be considered as clinically relevant in approximately 60% of the patients. This 
improvement didn’t seem to be selectively associated with demographic or clinical 
characteristics of the patients, including clinical or biological response to infliximab or 
even steroid weaning. There was no significant difference when comparing median 
change in bone markers in luminal (treated with single infliximab infusion) and 
fistulizing CD (treated with three infliximab infusions).  
    Ryan et al.
61
 in a prospective trial studied 24 patients with active CD who were treated 
with infliximab (5mg/kg) for the first time. The majority of the patients had refractory 
luminal CD and only 2 patients had refractory luminal and fistulizing CD. There was no 
control group included in this study. 42% of the patients were on steroids and 50% of the 
patients were on calcium/Vitamin D supplements at the start of the study. Five time 
points were assayed, namely; baseline, 1-2, 4-6, 8-10 and 12-18 weeks post single 
infliximab infusion. In this study, infliximab infusion led to a significant increase in both 
markers of bone formation, b-ALP (p=0.022) and OC (p=0.008). Levels of both bone 
formation markers remained significantly increased even at 4 months post treatment. No 
significant change in serum N-telopeptide (sNTx) was observed although at 4 months 
post treatment, levels were lower than at baseline. Of particular interest, the benefit seen 
on bone metabolism with infliximab treatment appeared to occur independently of the 
clinical response in terms of effect on CD activity; however the trend of increase in both 
bone formation markers and decrease in bone resorption marker was greater in 
responders compared with non-responders. In this study as well, maximal reduction in 
CDAI was seen between 8 and 10 weeks, whereas bone formation markers continued to 
increase up to 16 weeks post treatment, suggesting that there might be a lag in the 
biological effect of the infliximab on bone metabolism.  
    Following on this, Abreu et al.
62
 in small, short prospective study involving 38 
refractory CD patients reported a significant increase in b-ALP (p=0.010) whereas serum 
NTx, was not increase (p=0.801) at week 4 compared to baseline post a single infliximab 
infusion. This study again did not compare its findings with an age matched control 
group. In this study sera were also analyzed for immunoreactive parathyroid hormone 
(iPTH), calcium and pro-inflammatory cytokines (IL-1α, IL-6, and TNF-α) at baseline 
and 4 weeks following infliximab infusion. Overall, treatment with infliximab was 
associated with a statistically significant decrease in PTH levels (p=0.008) and 
statistically significant increase in serum calcium (p=0.034) at week 4. No significant 
changes in serum cytokine measurements from baseline to week 4 were noted. In this 
study the authors also sub analyzed the data based on whether the patients were receiving 
glucocorticoids at the time of their initial infliximab infusion and whether patients were 
responders or non-responders. 22/38 (57.9%) patients were receiving glucocorticoids at 
their time of initial infliximab infusion. The increase in bone formation occurred in both 
glucocorticoid treated individuals and those not on glucocorticoid, concluding that 
glucocorticoid use is not the principal reason for osteoporosis in patients with CD. 
Importantly, in this study the effect was also seen in both infliximab responders and non-
responders, suggesting an independent effect of infliximab on bone metabolism.  
    Miheller et al.
63
 in a small study studied the effect of infliximab on bone formation and 
resorption marker in 27 fistulizing CD patients and compared the results with 54 patients 
with inactive CD who acted as controls. Again, this was a short term study of just 42 
days, and in treated patients, there were significant difference in β-CrossLaps (bCL), a 
marker for bone resorption  on days 0 and 14 (p<0.01) and days 0 and 42 (p<0.05). OC 
levels increased significantly between day 0 and 42 (p<0.05) confirm the results from 
previous studies that infliximab has beneficial effects on bone turnover markers in CD 
patients.  
 
INFLIXIMAB AND BONE MINERAL DENSITY 
    To date, few published studies have examined the effect of infliximab on bone loss in 
CD patients by measuring BMD. A retrospective cohort analysis was performed by 
Pazianas et al.
64
 on 61 patients with CD and low BMD as measured by DXA scans. 23 
patients were on infliximab and 36 patients were on bisphosphonates. Mean duration 
between DXA scans was 2.2 +/- 0.99 years. After controlling for corticosteroids use, 
patients with concurrent infliximab and bisphosphonate treatment exhibited a greater 
increase in BMD compared to those on bisphosphonate alone (+6.7%/year vs. 
+4.46%/year,p=0.045); corticosteroids inhibited this effect (p=0.025). However, 
infliximab alone had no effect on BMD. In this study, only lumbar spine BMD 
measurements were included for analysis and there were no control group. 
    In another retrospective study by Mauro et al.
65
 data from 15 patients with CD who 
had received treatment with infliximab for the first time and who underwent DXA before 
and during infliximab treatment were compared with 30 CD patients who had never 
received treatment with infliximab and who had two DXA evaluations at least 12 months 
apart. Patients in this study received infliximab (5m/kg) at intervals of four to eight 
weeks for a mean period of 18 months. The first and second DXA evaluations were 22.6 
+/-11 months apart in the infliximab group and 20.4 +/- 8 months apart in the control 
group. The infliximab group had a significant increase in lumbar bone area, bone mineral 
content (BMC) and BMD between both evaluations compare to control (CD patients who 
had never received infliximab). The increase in BMC, i.e. the bone mass measurements 
in patients who had received infliximab treatment was significant when compared with 
control patients who had received glucocorticoids (n=8) or who had evidence of disease 
activity. 
    Bernstein et al.
66
 also found that maintenance treatment with infliximab (5mg/kg) at 6-
8 weeks intervals for 1 year in 46 CD patients improved BMD after one year in the 
lumbar spine (2.4% increase, p=0.002), at the femoral trochanter by (2.8% 
increase,p=0.03), and at the femoral neck by (2.6% increase,p=0.001) and that this effect 
was independent of concurrent administration of glucocorticoids, calcium 
supplementation, or changes in C-reactive protein. Also BMD gain at the lumbar spine 
and the left femur between the groups without and with osteopenia were not different. 
However, this study did not have a control group to compare differences in the changes in 
BMD. 
 
INFLIXIMAB AND OSTEOCLASTOGENESIS MARKERS  
    Only one study has evaluated changes of osteoclastogenesis markers (OPG and 
RANKL) with infliximab therapy. Miheller et al.
67
 studied 29 refractory CD patients who 
were treated with infliximab at week 0, 2 and 6. In 19 cases CD was associated with 
fistulas. There were no postmenopausal females in this cohort, and all of these patients 
were steroid free for at least 1 month before the first infliximab infusion. No patients in 
this study had been treated with bisphosphonates or vitamin D. Six patients were on 
calcium supplements. Serum OC as a bone formation marker, serum beta-crosslaps (bCL) 
as a marker of bone resorption, serum OPG, and serum RANKL were measured before 
each course of infliximab therapy. BMD measurements were also performed at baseline 
in all patients using a DXA scan. In this study, four of 29 patients had osteoporosis and 
14 of 29 had osteopenia. Serum levels of bone formation marker (OC) and RANKL 
increased after infliximab therapy at week 6, while concentrations of bone resorption 
marker (bCL) and OPG decreased at the same time. Femoral BMD correlated with 
baseline serum bCL and sRANKL concentrations (0.548; p<0.05 and 0.532; p<0.05). 
There were no significant correlations between bone remodeling markers (OC and bCL) 
and osteoclastogenesis markers (OPG and sRANKL) and lumbar BMD.  The authors 
concluded that elevated OPG in CD could be a counter-regulatory response to 
inflammatory cytokines or may reflect T-cell activation. 
 
ADALIMUMAB  
     Adalimumab is a human IgG1 monoclonal antibody specific for human TNF. Unlike, 
infliximab which requires an intravenous infusion, adalimumab is administered by 
subcutaneous injection.
68
 Adalimumab has been recently approved for the treatment of 
active CD. The clinical efficacy and safety of adalimumab in patients with moderate to 
severe CD has been demonstrated in four pivotal studies.
69-72
  All these studies have 
shown adalimumab to be superior to placebo for inducing and maintaining remission. 
Maintenance adalimumab therapy is administered as a subcutaneously every two weeks. 
The approved induction dosing of adalimumab in CD is 160 mg given subcutaneously 
initially at week zero, 80 mg at week two, followed by a maintenance dose of 40 mg 
every other week beginning at week four. The drug is available in a single-use prefilled 
pen (HUMIRA Pen) or in a single-use, prefilled glass syringe.  At present time, 
adalimumab is only licensed for use in CD patients.  
 
ADALIMUMAB AND BONE METABOLISM IN IBD  
     To the best of our knowledge, there are currently no published data investigating the 
effect of adalimumab on bone metabolism in IBD patients. However, one such report 
exists studying BMD in a population of RA patients treated for 1 year with 
adalimumab.
73
 In this study, fifty patients with active RA (defined as having a 28-joint 
disease activity score (DAS28) of ≥ 3.2) who started adalimumab treatment (40 mg 
subcutaneously every other week) were included in an open label prospective study. The 
BMD of both the lumbar spine (L1-L4) and left femoral neck was measured before 
treatment and after one year by DXA. Both disease activity at baseline (DAS28) and 
disease duration were inversely correlated with femoral neck BMD and lumbar spine 
BMD (p<0.05). Mean BMD of both lumbar spine and femur neck remained unchanged 
after one year of adalimumab therapy (+0.3% and +0.3%, respectively). The authors 
concluded that their result shows that with adalimumab therapy, progression of bone loss 
is halted. Measurements of bone turnover markers were not performed in this study 
though and there was no control group.  
 
SUMMARY  
     The data, albeit slightly limited, available to date strongly suggest that infliximab has 
beneficial effect on bone metabolism in CD patients. The beneficial effect does seem to 
be heterogeneous in aetiology and to vary from patient to patient. Primarily, the main 
beneficial effect appears to be related to an increase in bone formation although a 
decrease in bone resorption also appears to play a role in some patients. The effects seem 
to be independent of whether the response and non-response to treatment based on 
clinical score. Furthermore, the beneficial effects on bone metabolism appear to be 
independent of steroid therapy. Case-control studies (which are few) indicated that CD 
patients in general had lower bone formation markers and higher bone resorption markers 
as compared to healthy subjects and that infliximab therapy reverses this balance. 
Patients who received infliximab have also been shown to increase BMD during therapy.    
     It’s likely that several different mechanisms play a role in this positive effect of 
infliximab on bone metabolism Firstly, neutralization of TNF-α, which has a beneficial 
effect on bone metabolism in vitro, might also play a role in vivo.
74,75
 Secondly, 
infliximab reduces elaboration of a host of other pro-inflammatory cytokines such as IL-6 
and IL-1β53 which also has a deleterious effect on bone metabolism25,32 thus reduction of 
the inflammatory response in general is likely to play a pivotal role. A third possible 
mechanism is that improvement in general well being and physical activity might also 
improve net bone formation. Fourthly, by reducing gut inflammation, infliximab can 
improve bone metabolism indirectly by increase in resorption of the crucial bone 
nutrients required for bone formation.  
 
 
 
 Study Number 
of 
patients 
Underlying 
condition 
Control 
group 
(No of 
patients) 
Number of 
infliximab 
infusions 
Bone 
formation 
markers 
measured 
Bone 
resorption 
makers 
measured 
Bone 
mineral 
density 
evaluated 
Bone 
nutrients 
measured 
OPG/ 
RANKL 
measured 
Time point 
measured 
Major conclusion 
Franchimont et 
al 
60
 
71 CD (21 
fistulizing, 
50 luminal) 
Healthy 
subjects 
(68) 
1 (for 
luminal 
disease);       
3 (for 
fistulizing 
disease) 
Yes                 
(b-ALP, 
OC, 
P1NP) 
Yes 
(sCTx) 
No No No At baseline 
and 8 weeks 
post 
infliximab 
↑ bone formation 
markers; ↓ bone 
resoprtion marker at 
8 weeks post 
infliximab. Rapid 
normalization of 
formation and 
resorption markers 
noted to the level of 
controls with 
infliximab 
Ryan et al 
61
 24 CD (2 had 
fistulizing) 
No 1 Yes             
(b-ALP, 
OC) 
Yes 
(sNTx) 
No No No At baseline,1-
2, 4-6, 8-10, 
12-18 weeks 
post 
infliximab 
 Significant ↑ in both 
markers of bone 
formation, b-ALP 
and OC. Levels 
remained 
significantly ↑ even 
at 4 months post 
treatment. No 
significant change in 
sNTx was observed 
although at 4 months 
post treatment, levels 
were lower than at 
baseline.  
Abreu et al 
62
 38 CD No 1 Yes             
(b-ALP) 
Yes 
(sNTx) 
No Yes 
(iPTH; 
Calcium) 
No At baseline 
and 4 weeks 
post 
infliximab 
↓ in PTH and ↑ in 
calcium at week 4. ↑ 
in bone formation 
marker occurred in 
both glucocorticoid 
treated and those not 
on glucocorticoid 
patients 
Miheller et al
 63
 27 CD (all 
fistulizing) 
Yes         
(54- 
inactive 
CD) 
3 Yes (OC) Yes            
(b-CL) 
No No No At baseline, 
week 2 and 
week 6 post 
infliximab 
Significant ↑ in OC 
at week 6 noted, and 
significant difference 
noted of b-CL on 
days 0 and 14 and 
days 0 and 42 
Pazianas et al 
64
  
(retrospective 
study) 
61 CD No Not 
mentioned 
No No Yes No No Mean 
duration 
between 
DEXA scans 
were 2.2 +/- 
0.99 years  
Patients on 
concurrent 
infliximab and 
bisphosphonates had 
increase in BMD 
compared to 
bisphosponates 
alone. Infliximab 
alone had no effect 
on BMD 
Mauro et al 
65 
(retrospective 
study) 
15 CD 30 CD 
patients 
who had 
no 
infliximab 
treatment 
Maintenance 
therapy 
every 4-8 
weeks for a 
mean of 18 
months 
No No Yes No No 1st and 2nd 
DEXA were 
22.6+/-11 
months apart 
in the 
infliximab 
group and 
20.4 +/- 8 
months apart 
in the control 
group 
The infliximab group 
had a significant 
increase in lumbar 
bone area, bone 
mineral content and 
BMD compared to 
control group.  
  
Table 1: Summary of published articles looking at the effect of infliximab on bone metabolism in IBD patients.  
      
 
Bernstein et al 
66
 
46 CD No Maintenance 
therapy 
every 6-8 
weeks for 1 
year 
No No Yes No No At baseline 
and 1 year 
post 
infliximab 
treatment 
Improved BMD after 
1 year in the lumbar 
spine (p=0.002), 
femoral trochanter 
(p=0.03) and at 
femoral neck 
(p=0.001) and this 
was independent of 
concurrent 
administration of 
glucocorticoids, 
calcium 
supplementation or 
changes in CRP. 
Miheller et al
 67
 29 CD (19 
fistulizing) 
No 3 Yes (OC) Yes            
(b-CL) 
Yes (only 
at 
baseline)       
No Yes At baseline, 
week 2 and 
week 6 post 
infliximab 
Serum levels of OC 
and RANKL 
increased, while bCL 
and OPG decreased 
at week 6. Femoral 
BMD correlated with 
basic serum bCL and 
sRANKL.  
  
CONCLUSION 
     To date, studies looking at the effects of anti-TNF-α therapy on bone metabolism in 
IBD patients are limited, and have only evaluated the role of infliximab on bone 
metabolism in CD patients. No studies have yet evaluated the effects of adalimumab 
therapy on bone metabolism in IBD patients or the effect of anti-TNF α therapy in UC 
patients. Furthermore, currently available studies have only been carried out for short 
term, with the longest being for 14 weeks.
61
 Hence the long term effect of maintenance 
therapy with anti-TNF-α on bone metabolism in IBD patients is not known. Moreover, 
the effects of these therapies on bone cells have not yet been studied. This is crucial to 
understanding the direct effect of anti-TNF-α on bone cells. Long term studies are also 
needed to compare changes in cytokines, osteoclastogenesis markers (OPG and 
RANKL), bone nutrients (PTH and vitamin D) and most importantly on BMD to fully 
understand the mechanisms involved. Finally, what happens to the beneficial effects seen 
on bone metabolism in IBD patients following cessation of anti-TNF-α therapy is not 
known. Properly controlled long term trials are necessary to fully evaluate the effects of 
TNF blockers in this regard.  
 
ACKNOWLEDGMENT 
Declaration of personal interest: Prof. Colm O'Morain is on the international advisory 
board of Abbott, Schering Plough and Shire pharmaceutical companies.  
Declaration of funding interests: None.    
   REFERENCES  
 
1. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extra-
intestinal manifestations in first-degree familial and sporadic inflammatory bowel 
disease: A case control study. Inflamm Bowel Dis 2004; 10: 207-14. 
2. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of 
inflammatory bowel disease: A prospective study of 792 patients. J Clin 
Gastroenterol 1996; 23: 29-34.  
3. Lakatos L, Pandur T, David G, et al. Association of extra-intestinal manifestations 
of inflammatory bowel disease in a province or western Hungary with disease 
phenotype: Results of a 25-year follow-up study. World J Gastroenterol 2003; 9: 
2300-7.  
4. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease 
and decreasing surgery rates in Copenhagen City and County, 2003-2005: A 
population-based study from the Danish Crohn Colitis Database. Am J 
Gastroenterol 2006; 101: 1274-82. 
5. Genant, HK, Mall, JC, Wagonfeld, JB, et al. Skeletal demineralization and growth 
retardation in inflammatory bowel disease. Invest Radiol 1976; Nov-Dec; 11(6): 
541-9. 
6. Vestergaard P, Mosekilde F. Fracture risk in patients with coeliac disease, 
Crohn’s disease, and ulcerative colitis: A nationwide follow-up study of 16416 
patients in Denmark. Am J Epidemiol 2002; 156: 1-10. 
7. Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory 
bowel disease and their relationship to corticosteroid use: A population based 
cohort study. Gut 2004; 53: 251-5. 
8. Silvennoinen JA. Relationship between vitamin D, parathyroid hormone and bone 
mineral density in inflammatory bowel disease. J Int Med 1996; 239: 131-7. 
9. Bischoff SC, Herrmann A, Goke M, et al.  Altered bone metabolism in 
inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1157-63. 
10. Silvennoinen JA, Karttunen TJ, Niemelia SE, et al. A controlled study of bone 
mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6. 
11. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone mineral density in 
inflammatory bowel disease is related to corticosteroid use and not disease 
diagnosis. J Bone Miner Res 1995; 10: 250-6. 
12. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with 
asthma. N Engl J Med 1983; 309: 265-8. 
13. Compston JE. Detection of osteoporosis in patients with inflammatory bowel 
disease. Eur J Gastroenterol Hepatol 1997; 9: 931-3. 
14. Robinson RJ, Iqbal SJ, Al-Azzani F, et al. Sex hormone status and bone 
metabolism in men with Crohn’s disease. Aliment Pharmacol Ther 1998; 12: 21-
5. 
15. Szulc P, Meunier PJ. Is vitamin-K deficiency a risk factor for osteoporosis in 
Crohn’s disease? Lancet 2001; 357: 1995-6. 
16. Hyams JS, Wyzga N, Kreutzer DL, et al. Alterations in bone metabolism in 
children with inflammatory bowel disease: An in vitro study. J Pediatr 
Gastroenterol Nutr 1997; 24: 289-95. 
17. Abitol V, Roux C, Chaussade S et al. Metabolic bone assessment in patients with 
inflammatory bowel disease. Gastroenterology 1995; 108: 417-22. 
18. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients 
with Crohn’s disease but not in patients with ulcerative colitis. Gut 1997; 40: 313-
9. 
19. Robinson RJ, Krzywicky T, Almond L et al. Effect of low-impact exercise 
program on bone mineral density in Crohn’s disease. A randomized controlled 
study. Gastroenterology 1998; 115: 36-41. 
20. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis 
in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 
1895-1902. 
21. Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble 
tumor necrosis factor-receptor are protected against bone loss caused by estrogen 
deficiency. J Clin Invest 1997; 99: 1699– 703.  
22. Bickel M, Axtelius B, Solioz C, et al Cytokine gene expression in chronic 
periodontitis. J Clin Periodontol 2001; 28: 840– 7.  
23. Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of 
osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002; 4: 281– 9.  
24. Origuchi T, Migita K, Nakashima T, et al. IL-1-mediated expression of membrane 
type matrix-metalloproteinase in rheumatoid osteoblasts. Clin Exp Rheumatol 
2000; 18: 333– 9.  
25. Oelzner P, Franke S, Muller A, et al. Relationship between soluble markers of 
immune activation and bone turnover in post-menopausal women with 
rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 841– 7.  
26. Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the 
pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a 
study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002; 41: 
329– 37.  
27. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour 
necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 
32: 913– 7.  
28. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of 
patients with inflammatory bowel disease as measured by a highly sensitive 
immuno-PCR. Clin Chem 2001; 47: 1297– 301. 
29. Lanfranchi GA, Tragnone A. Serum and faecal tumour necrosis factor-alpha as 
marker of intestinal inflammation. Lancet 1992; 339(8800): 1053.  
30. Lin, CL, Moniz, C, Chambers, TJ, et al. Colitis causes bone loss in rats through 
suppression of bone formation. Gastroenterology 1996; 111: 1263.  
31. Kumar S, Votta BJ, Rieman DJ, et al. IL-1- and TNF-induced bone resorption is 
mediated by p38 mitogen activated protein kinase. J Cell Physiol 2001; 187: 294– 
303.  
32. Sylvester FA, Wyzga N, Hyams JS, et al. Effect of Crohn's disease on bone 
metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002; 17: 695– 
702.  
33. Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-alpha 
(TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 
receptor and RANK signaling pathways. J Biol Chem 2001; 276: 563–8.  
34. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by 
direct stimulation of macrophages exposed to permissive levels of RANK ligand. 
J Clin Invest 2000; 106: 1481–8.  
35. Zou W, Hakim I, Tschoep K, et al. Tumor necrosis factor-alpha mediates RANK 
ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell 
Biochem 2001; 83: 70– 83.  
36. Fuller K, Murphy C, Kirstein B, et al. TNF alpha potently activates osteoclasts, 
through a direct action independent of and strongly synergistic with RANKL. 
Endocrinology 2002; 143: 1108–18.  
37. Lee SE, Chung WJ, Kwak HB, et al. Tumor necrosis factor-alpha supports the 
survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001; 
276: 49343–9.  
38. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor 
necrosis factor-alpha. Endocrinology 2000; 141: 3956–64.  
39. Taichman RS, Hauschka PV. Effects of interleukin-1 beta and tumor necrosis 
factor-alpha on osteoblastic expression of osteocalcin and mineralized 
extracellular matrix in vitro. Inflammation 1992; 16: 587–601. 
40. Pfeilschifter J, Chenu C, Bird A, et al. Interleukin 1 and tumour necrosis factor 
stimulate the formation of human osteoclast like cells in vitro. J Bone Miner Res 
1989; 4: 113-18. 
41. Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin 1 beta and tumour 
necrosis factor α, but not interleukin 6, stimulate osteoprotegerin ligand gene 
expression in human osteoblastic cells. Bone 1999; 25: 255-59. 
42. Hofbauer LC, Dunstan CR, Spelsberg TC, et al.  Osteoprotegerin production by 
human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic 
protein-2, and cytokines. Biochem Biophys Res Commun. 1998; 250: 776-81. 
43. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour 
necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically 
normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39(5): 
684-9. 
44. Lichtenstein GR. Evaluation of bone mineral density in IBD: Current safety focus. 
Am J Gastroenterol 2003; 98(suppl 12): S24–30. 
45. Nanes MS. TNF-alpha: Molecular and cellular mechanisms in skeletal pathology. 
Gene 2003; 321: 1–15. 
46. Aubin, JE, Bonnelye, E. Osteoprotegerin and its ligand: a new paradigm for 
regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000; 
11(11): 905-13. 
47. Kong, YY, Boyle, WJ, Penninger, JM. Osteoprotegerin ligand: a common link 
between osteoclastogenesis, lymph node formation and lymphocyte development. 
Immunol Cell Biol 1999; Apr; 77(2): 188-93. 
48. Kong, YY, Feige, U, Sarosi, I, et al. Activated T cells regulate bone loss and joint 
destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; Nov 
18; 402(6759): 304-9. 
49. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal 
antibody cA2 binds recombinant transmembrane TNF-alpha and activates 
immune effector functions. Cytokine 1995; 7(3): 251-9. 
50. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy 
in patients with ulcerative colitis. Am J Gastroenterol 2002; 97(10): 2577-84. 
51. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in 
monocytes from patients with chronic active Crohn's disease by using a caspase-
dependent pathway. Gastroenterology 2001; 121(5): 1145-57. 
52. Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment 
induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 
50(2): 206-11. 
53. Van den Brande JM, Braat H, Van den Brink GR, et al. Infliximab but not 
etanercept induces apoptosis in lamina propria T-lymphocytes from patients with 
Crohn's disease. Gastroenterology 2003; 124(7): 1774-85. 
54. Targan SR, Hanauer SB, Van Deventer SJ, et al.  A short-term study of chimeric 
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. 
Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15): 1029-35. 
55. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for 
Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541-
9.   
56. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas 
in patients with Crohn's disease. N Engl J Med 1999; 340(18): 1398-405.   
57. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for 
fistulizing Crohn's disease. N Engl J Med 2004; 350(9): 876-85. 
58. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and 
episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 
2004; 126: 402-13. 
59. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and 
maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462-76. 
60. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone 
metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol 
Ther 2004; 20: 607-14. 
61. Ryan BM, Russel MGVM, Schurgers L, et al. Effect of antitumour necrosis 
factor-α therapy on bone turnover in patients with active Crohn’s disease: a 
prospective study. Aliment Pharmacol Ther 2004; 20: 851-7. 
62. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is 
associated with increased markers of bone formation in patients with Crohn's 
disease. J Clin Gastroenterol 2006; 40(1): 55-63.  
63. Miheller P, Muzes G, Zagoni T, et al. Infliximab therapy improves the bone 
metabolism in fistulizing Crohn's disease. Dig Dis 2006; 24(1-2): 201-6.  
64. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy 
on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci 
2006; 1068: 543-56.  
65. Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after 
infliximab therapy in Crohn's disease patients. Can J Gastroenterol 2007; 21(10): 
637-42.  
66. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is 
associated with improved bone mineral density in Crohn's disease. Am J 
Gastroenterol 2005; 100(9): 2031-5. 
67. Miheller P, Muzes G, Rácz K, et al. Changes of OPG and RANKL concentrations 
in Crohn's disease after infliximab therapy. Inflamm Bowel Dis 2007; 13(11): 
1379-84. 
68. Plosker G.L., Lyseng-Williamson K.A. Adalimumab; in Crohn’s disease. 
Biodrugs 2007; 21(2): 125-32. 
69. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor 
monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. 
Gastroenterology 2006; 130(2): 323-33. 
70. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of 
clinical response and remission in patients with Crohn's disease: the CHARM 
trial. Gastroenterology 2007; 132(1): 52-65. 
71. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for 
Crohn disease previously treated with infliximab. Ann Intern Med 2007; 146(12): 
829-38. 
72. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance 
treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56(9): 
1232-9. 
73. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in 
rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss? 
Ann Rheum Dis 2009; 68(30): 373-6. 
74. Zou W, Hakim I, Tschoep K, et al. Tumour necrosis factor-alpha mediates RANK 
ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell 
Biochem 2001; 83: 70-83. 
75. Abu-Amer Y, Erdmann J, Alexopoulou L, et al. Tumour necrosis factor receptors 
types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000; 275: 
27307-10. 
